Financials data is unavailable for this security.
View more
Year on year Beijing Konruns Pharmaceutical Co Ltd grew revenues 6.15% from 866.73m to 920.01m while net income improved 48.24% from 101.49m to 150.45m.
| Gross margin | 88.30% |
|---|---|
| Net profit margin | 19.62% |
| Operating margin | 14.14% |
| Return on assets | 4.50% |
|---|---|
| Return on equity | 4.41% |
| Return on investment | 5.31% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Beijing Konruns Pharmaceutical Co Ltd fell by 106.11m. However, the company earned 199.35m from its operations for a Cash Flow Margin of 21.67%. In addition the company generated 143.62m cash from financing while 447.72m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 19.63 |
|---|---|
| Tangible book value per share | 12.55 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.13 |
|---|---|
| Quick ratio | 2.93 |
| Total debt/total equity | 0.05 |
|---|---|
| Total debt/total capital | 0.0435 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 50.00% and 45.92%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 0.69% |
|---|---|
| Div growth rate (5 year) | -9.71% |
| Payout ratio (TTM) | 34.87% |
| EPS growth(5 years) | -13.73 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 20.40 |
More ▼
